Format

Send to

Choose Destination
Mol Ther. 2016 Feb;24(1):87-95. doi: 10.1038/mt.2015.146. Epub 2015 Aug 12.

Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.

Hardet R1,2, Chevalier B1,2, Dupaty L1,2, Naïmi Y1,2, Riou G1,2, Drouot L1,2, Jean L1,2, Salvetti A3,4,5,6, Boyer O1,2,7, Adriouch S1,2.

Author information

1
Inserm, U905, Rouen, France.
2
Normandie University, Institute for Research and Innovation in Biomedicine, Rouen, France.
3
International Center for Research in Infectiology (CIRI), Inserm U1111, CNRS UMR5308, Lyon, France.
4
Ecole Normale Supérieure de Lyon, Lyon, France.
5
Université de Lyon, UCB-Lyon1, Lyon, France.
6
LabEx Ecofect, Université de Lyon, Lyon, France.
7
Rouen University Hospital, Department of Immunology, Rouen, France.

Abstract

Gene therapy represents a feasible strategy to treat inherited monogenic diseases and intramuscular (i.m.) injection of recombinant adeno-associated viral (AAV) vector is now recognized as a convenient and safe method of gene transfer. However, this approach is hampered by immune responses directed against the vector and against the transgenic protein. We used here to reproduce this situation a mouse model where robust immune responses are induced following injection of an AAV vector coding for an immunogenic transgenic protein. We show that prophylactic oral administration of the immunogenic protein before AAV-mediated gene transfer completely prevented antibody formation and cytotoxic CD8(+) T-cell response. Consistently, prophylactic oral-tolerization considerably improved long-term transgene persistence and expression. Mechanistically, inhibition of the cytotoxic immune response involved abortive proliferation of antigen-specific cytotoxic CD8(+) T cells, upregulation of the PD-1 immunoregulatory molecule, downregulation of the Bcl-2 antiapoptotic factor, and their deletion in the context of AAV-mediated gene transfer. Hence, gene therapy may represent an ideal situation where oral-tolerization can be adopted before or at the same time as vector injection to efficiently prevent deleterious immune responses directed against the transgenic protein.

PMID:
26265250
PMCID:
PMC4754539
DOI:
10.1038/mt.2015.146
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center